Profile data is unavailable for this security.
About the company
Dishman Carbogen Amcis Limited is engaged in contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules, such as specialty chemicals, vitamins and chemicals, and disinfectants. The Company's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The Company assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The Company has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The Company's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
- Revenue in INR (TTM)22.86bn
- Net income in INR-152.40m
- Incorporated2007
- Employees1.17k
- LocationDishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
- Phone+91 2 717420102
- Fax+91 7 926420198
- Websitehttps://www.carbogen-amcis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGL Fine-Chem Ltd | 2.96bn | -781.07m | 10.25bn | 329.00 | -- | 4.95 | -- | 3.47 | -126.42 | -126.42 | 478.66 | 334.81 | 1.09 | 5.13 | 5.33 | 8,981,979.00 | -28.88 | 17.96 | -38.13 | 24.18 | 15.88 | 48.76 | -26.43 | 14.83 | 1.94 | -53.65 | 0.1327 | 2.93 | 23.08 | 24.42 | -12.03 | 27.37 | 22.93 | -- |
| Bajaj Healthcare Ltd | 7.16bn | 632.95m | 10.88bn | 1.05k | 17.20 | 3.05 | 12.74 | 1.52 | 22.93 | 22.93 | 259.42 | 129.31 | 0.9665 | 3.12 | 3.87 | 6,808,470.00 | 8.54 | 11.38 | 15.78 | 19.70 | 25.76 | 25.65 | 8.84 | 8.64 | 0.7166 | 5.78 | 0.4949 | -- | 3.49 | 24.14 | -14.11 | 55.61 | 50.96 | -- |
| Medicamen Biotech Ltd | 1.22bn | 137.13m | 10.93bn | 357.00 | 77.67 | 5.88 | 54.79 | 8.96 | 11.12 | 11.12 | 98.97 | 146.87 | 0.5281 | 2.94 | 1.95 | 3,417,785.00 | 5.94 | 8.02 | 8.16 | 11.97 | 51.08 | 33.66 | 11.24 | 10.62 | 1.77 | 6.78 | 0.1329 | 9.01 | 2.42 | 6.96 | 22.82 | 23.62 | 29.99 | 0.00 |
| TTK Health Care Ltd | 6.80bn | 226.35m | 12.68bn | 2.59k | 55.98 | 1.37 | 35.18 | 1.86 | 16.03 | 448.38 | 481.19 | 656.99 | 0.7702 | 4.50 | 9.10 | 2,626,766.00 | 2.56 | 5.08 | 3.59 | 8.37 | 50.93 | 56.70 | 3.33 | 3.76 | 3.53 | 1.37 | 0.0248 | 34.31 | 25.88 | 2.57 | -49.68 | -0.2463 | 3.72 | 14.87 |
| Suven Life Sciences Ltd. | 165.80m | -939.96m | 14.05bn | 117.00 | -- | 18.01 | -- | 84.77 | -6.43 | -6.43 | 1.12 | 3.58 | 0.181 | 0.00 | 11.02 | 1,417,077.00 | -102.59 | -9.45 | -165.56 | -10.92 | 78.65 | 65.15 | -566.93 | -19.84 | 1.32 | -252.26 | 0.4792 | -- | -12.12 | -53.49 | -69.08 | -- | -8.33 | -- |
| Morepen Laboratories Ltd | 14.70bn | 552.86m | 14.75bn | 2.38k | 26.55 | 2.00 | 17.80 | 1.00 | 1.09 | 1.09 | 28.88 | 14.41 | 1.41 | 4.39 | 6.14 | 6,182,353.00 | 5.29 | 8.25 | 8.53 | 17.08 | 32.51 | 33.95 | 3.76 | 5.86 | 1.64 | 27.65 | 0.03 | 0.00 | 30.20 | 21.04 | 4.73 | 33.89 | 46.89 | -- |
| RPG Life Sciences Limited | 4.83bn | 603.30m | 14.97bn | 1.17k | 24.81 | 5.39 | 19.77 | 3.10 | 36.49 | 36.49 | 292.16 | 168.05 | 1.38 | 2.12 | 8.94 | 4,146,781.00 | 17.20 | 10.28 | 22.80 | 14.95 | 66.60 | 61.70 | 12.49 | 7.69 | 1.71 | 194.56 | 0.0015 | 27.43 | 13.11 | 7.49 | 28.70 | 33.61 | -15.58 | 27.94 |
| Dishman Carbogen Amcis Ltd | 22.86bn | -152.40m | 15.50bn | 1.17k | -- | 0.279 | 5.20 | 0.6781 | -0.968 | -0.968 | 146.44 | 354.25 | 0.2633 | 0.7953 | 5.42 | 19,568,840.00 | -0.1756 | 0.9727 | -0.2117 | 1.17 | 76.82 | 74.41 | -0.6668 | 3.82 | 0.7179 | 0.1305 | 0.2685 | 103.41 | 11.96 | 4.55 | 110.91 | -34.15 | 25.67 | -- |
| Novartis India Ltd | 4.20bn | 537.10m | 16.27bn | 81.00 | 30.29 | 2.20 | 26.91 | 3.88 | 21.75 | 21.75 | 169.92 | 299.32 | 0.426 | 4.45 | 9.08 | 51,817,280.00 | 5.45 | 3.13 | 6.62 | 3.97 | 51.96 | 57.42 | 12.80 | 7.18 | 3.46 | 19.27 | 0.0289 | 75.56 | 4.86 | -9.43 | -117.80 | -- | -29.15 | 0.00 |
| Orchid Pharma Ltd | 6.36bn | -356.44m | 16.34bn | 1.80k | -- | 2.63 | 28.60 | 2.57 | -8.72 | -10.00 | 155.37 | 152.33 | 0.5576 | 1.73 | 4.86 | -- | -2.55 | -4.56 | -3.26 | -9.13 | 42.66 | 50.02 | -4.58 | -18.16 | 0.8107 | -0.4843 | 0.3531 | -- | 24.33 | -7.07 | 36.56 | -- | 10.67 | -- |
| Hester Biosciences Ltd | 2.36bn | 271.17m | 16.51bn | 584.00 | 62.57 | 6.25 | 34.47 | 6.99 | 31.01 | 31.01 | 266.54 | 310.44 | 0.4478 | 0.9273 | 3.61 | 4,041,199.00 | 5.22 | 9.77 | 6.34 | 12.19 | 72.69 | 70.76 | 11.65 | 17.84 | 1.19 | 3.86 | 0.4966 | 24.00 | 9.65 | 13.38 | 14.20 | 10.80 | 25.91 | 13.54 |
| Solara Active Pharma Sciences Ltd | 11.30bn | -1.64bn | 16.96bn | 2.25k | -- | 1.13 | -- | 1.50 | -45.74 | -45.74 | 313.98 | 416.26 | 0.3816 | 1.29 | 1.91 | 5,011,535.00 | -5.56 | -- | -8.72 | -- | 40.39 | -- | -14.56 | -- | 0.5475 | -1.87 | 0.3934 | -- | -21.56 | -- | -126.26 | -- | -- | -- |
| Alembic Limited | 969.02m | 1.50bn | 18.69bn | 305.00 | 12.50 | 0.7737 | 23.43 | 19.29 | 5.83 | 5.83 | 3.77 | 94.10 | 0.0376 | 0.3862 | 6.68 | 3,177,115.00 | 2.86 | 3.40 | 2.94 | 3.52 | 68.69 | 50.21 | 76.23 | 58.12 | 0.9257 | 42.91 | 0.00 | -- | 6.39 | -11.87 | -35.23 | 8.84 | 20.12 | -- |
| Supriya Lifescience Ltd | 5.19bn | 1.28bn | 19.68bn | -- | 15.37 | 3.02 | 14.16 | 3.79 | 15.91 | 15.91 | 64.53 | 81.00 | 0.8196 | 2.11 | 6.28 | -- | 20.22 | -- | 24.98 | -- | 60.40 | -- | 24.67 | -- | 4.38 | 8.52 | 0.0529 | -- | 37.54 | -- | 22.60 | -- | -- | -- |
| Amrutanjan Health Care Ltd | 3.99bn | 517.13m | 20.59bn | 647.00 | 39.93 | 7.56 | 36.53 | 5.16 | 17.67 | 17.67 | 136.30 | 93.39 | 1.17 | 7.10 | 11.51 | 6,165,725.00 | 15.22 | 18.30 | 19.61 | 22.82 | 53.43 | 54.97 | 12.96 | 13.46 | 2.90 | 151.07 | 0.0023 | 21.83 | 21.93 | 13.32 | 9.80 | 23.79 | 43.89 | 33.13 |
Data as of Nov 25 2022. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR
8.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HBM Partners AG (Investment Management)as of 30 Sep 2022 | 5.56m | 3.55% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Sep 2021 | 2.95m | 1.88% |
| L&T Investment Management Ltd.as of 31 Oct 2022 | 2.38m | 1.52% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2022 | 1.25m | 0.80% |
| Dimensional Fund Advisors LPas of 03 Nov 2022 | 1.22m | 0.78% |
| SSgA Funds Management, Inc.as of 03 Nov 2022 | 187.51k | 0.12% |
| quant Money Managers Ltd.as of 31 Oct 2022 | 132.55k | 0.09% |
| Dimensional Fund Advisors Ltd.as of 04 Nov 2022 | 51.87k | 0.03% |
| American Century Investment Management, Inc.as of 03 Nov 2022 | 22.10k | 0.01% |
| DFA Australia Ltd.as of 30 Sep 2022 | 4.02k | 0.00% |
More ▼
Data from 30 Sep 2022 - 23 Nov 2022Source: FactSet Research Systems Inc.
